Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.

NCT07771517 — Not yet recruiting, 90 participants, Sohag University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders

Registry	NCT07771517
Status	Not yet recruiting
Study type	Observational
Enrollment	90 (Estimated)
Sponsor	Sohag University (Other)
Conditions	Major Depressive Disorder (MDD)
Dates	start 2027-03-14 (estimated), primary completion 2028-08-20 (estimated), completion 2029-05-20 (estimated), first posted 2026-08-18, last updated 2026-08-20

-Summary

This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits

Expand all sections · Collapse all

+Outcome measures

Primary outcomes

Psychological assessment of patients with depressive disorders [From the enrollment of all cases till three months later]: All cases will be subjected to psychological assessment by using structured clinical interview for DSM-V to assess major depressive disorder,bipolar and other depressivedisorders, Hamilton depression rating scale HAN-D to assess MDD, Hamilton anxiety inventory HAM-A to assess anxiety disorders, Montreal cognitive assessment to assess cognitive functions, Pittsburg sleep quality index to assess quality of sleep and detailed family history will be obtained to assess possibility of genetic factors in health relatives to patients with depressive disorders.
Detect abnormalities in kynurenine pathway in patients with depressive disorders [From the time of enrollment till 3 months later]: Blood samples will be collected from patients and healthy control cases in microbiology laboratory in Sohag university hospital; by using biokits for kynurenine to measure kynurenine level in nanomolar to low micromolar in liter, Add a tryptophan measure outcome to measure tryptophan level in micromol per liter Add a quinolinic acid measure outcome to measure quinolinic acid level in microgram per milliliter by ELISA

+Eligibility

Sex: All, ages: 18 Years to 18 Years, accepts healthy volunteers

Inclusion Criteria:

* age group 18: 60 years old
* cases are drug free of at least 4 months

Exclusion Criteria:

* patients with comorbid other psychiatric disorders( SUD,anxiety)
* patients with IQ below 90
* patients with psychotic features
* patients with postpartum depression
* patients with chronic medical illness that might affect immune function
* patients under treatment with immune modulating therapy